Share

January 2020; 7 (1) Correction

IL6 receptor358Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis

First published December 5, 2019, DOI: https://doi.org/10.1212/NXI.0000000000000650
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
296

Share

See original article:

In the article “IL6 receptor358Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis” by Wosiski-Kuhn et al.,1 first published online October 14, 2019, the y-axis label in figure 1C should be “Serum sIL6R (ng/mL).” In figure 1E, the y-axis label should be “Serum sgp130 (ng/mL).” In figure 2A, the y-axis label should be “Serum sIL6R (ng/mL).” The editorial office regrets the errors.

Reference

  1. 1.↵
    1. Wosiski-Kuhn M,
    2. Robinson M,
    3. Strupe J, et al
    . IL6 receptor358Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm 2019;6:e631. doi: 10.1212/NXI.0000000000000631.
    OpenUrlAbstract/FREE Full Text

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Alert Me

Recommended articles